Dr. Glaucomflecken Explains: Tenecteplase for Acute Central Retinal Artery Occlusion (TenCRAOS)
Why It Matters
The trial shows tenecteplase offers no visual benefit and adds risk, keeping CRAO management unchanged and highlighting the urgency for effective therapies.
Key Takeaways
- •Tenecteplase evaluated for acute CRAO within four‑and‑a‑half hours
- •Phase II NEJM trial enrolled seventy‑eight patients, randomizing to drug or placebo
- •Primary outcome: 30‑day visual recovery showed no significant difference
- •Serious adverse events occurred more frequently in the tenecteplase arm
- •Findings suggest thrombolysis not ready for routine CRAO management
Summary
The video features Dr. Glaucomflecken reviewing a recent New England Journal of Medicine trial that tested intravenous tenecteplase as an emergency treatment for acute central retinal artery occlusion (CRAO), a sudden, painless loss of vision often seen in older hypertensive patients.
In the randomized, double‑blind study, 78 adults presented within 4.5 hours of symptom onset and received either tenecteplase plus oral placebo or placebo plus oral aspirin. The primary endpoint—visual recovery at 30 days—did not differ statistically between groups, while the tenecteplase cohort experienced a higher rate of serious adverse events.
The host interjects with humor, noting that the emergency department has not seen an ophthalmologist since 1983 and that calling “Santa Claus” is the only alternative. He also highlights the trial’s negative result, emphasizing that thrombolysis did not improve outcomes and introduced additional risk.
The findings reinforce that thrombolytic therapy cannot yet replace standard care for CRAO, underscoring the need for rapid ophthalmology consultation and further research into safe, effective interventions.
Comments
Want to join the conversation?
Loading comments...